Marie Bartenschlager
Overview
Explore the profile of Marie Bartenschlager including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benning L, Bartenschlager M, Kim H, Morath C, Zeier M, Schnitzler P, et al.
Vaccines (Basel)
. 2024 Jul;
12(7).
PMID: 39066376
We recently showed that an adapted SARS-CoV-2 vaccine with wildtype and BA.4/BA.5 Omicron subtype epitopes induced a broad short-term immune response in hemodialysis patients. Antibodies with protective capacity were boosted...
2.
Janssen M, Leo A, Wolf C, Stenzinger M, Bartenschlager M, Brandt J, et al.
Int J Cancer
. 2024 May;
155(4):618-626.
PMID: 38721724
Immunocompromised patients are at high risk to fail clearance of SARS-CoV-2. Prolonged COVID-19 constitutes a health risk and a management problem as cancer treatments often have to be disrupted. As...
3.
Benning L, Bartenschlager M, Kim H, Kalble F, Nusshag C, Buylaert M, et al.
J Med Virol
. 2023 Dec;
95(12):e29303.
PMID: 38082556
The development of bivalent booster vaccines addresses the ongoing evolution of the emerging B.1.1.529 (omicron) variant subtypes that are known to escape vaccine-induced neutralizing antibody response. Little is known about...
4.
Speer C, Tollner M, Benning L, Bartenschlager M, Kim H, Nusshag C, et al.
Viruses
. 2023 Aug;
15(8).
PMID: 37632120
Emerging omicron subtypes with immune escape lead to inadequate vaccine response with breakthrough infections in immunocompromised individuals such as Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) patients. As AAV is considered...
5.
Stich M, Benning L, Speer C, Garbade S, Bartenschlager M, Kim H, et al.
J Med Virol
. 2023 Feb;
95(3):e28582.
PMID: 36794653
Data on cross-neutralization of the SARS-CoV-2 omicron variant more than 1 year after SARS-CoV-2 infection are urgently needed, especially in children, to predict the likelihood of reinfection and to guide...
6.
Kuhn T, Speer C, Morath C, Bartenschlager M, Kim H, Beimler J, et al.
Transplantation
. 2023 Jan;
107(5):1139-1150.
PMID: 36617671
Background: The impaired immune response to coronavirus disease 2019 (COVID-19) vaccination in kidney transplant recipients (KTRs) leads to an urgent need for adapted immunization strategies. Methods: Sixty-nine KTRs without seroconversion...
7.
Benning L, Morath C, Kuhn T, Bartenschlager M, Kim H, Beimler J, et al.
Front Med (Lausanne)
. 2022 Sep;
9:958293.
PMID: 36059830
Seroconversion rates after COVID-19 vaccination are significantly lower in kidney transplant recipients compared to healthy cohorts. Adaptive immunization strategies are needed to protect these patients from COVID-19. In this prospective...
8.
Stich M, Benning L, Speer C, Garbade S, Bartenschlager M, Kim H, et al.
Pediatrics
. 2022 Aug;
150(5).
PMID: 35953884
No abstract available.
9.
Benning L, Morath C, Bartenschlager M, Kim H, Reineke M, Beimler J, et al.
Am J Transplant
. 2022 Apr;
22(7):1873-1883.
PMID: 35384272
Seroconversion after COVID-19 vaccination is impaired in kidney transplant recipients. Emerging variants of concern such as the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants pose an increasing threat to these...
10.
Tollner M, Speer C, Benning L, Bartenschlager M, Nusshag C, Morath C, et al.
J Clin Med
. 2022 Mar;
11(6).
PMID: 35330069
Background: To characterize humoral response after standard anti-SARS-CoV-2 vaccination in Rituximab-treated patients and to determine the optimal time point after last Rituximab treatment for appropriate immunization. Methods: Sixty-four patients who...